{"pmid":32361409,"pmcid":"PMC7187813","title":"Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection?","text":["Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection?","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a severe acute respiratory syndrome that is called COVID-19. Clinical manifestations of COVID-19 include diarrhea, pneumonia, lymphopenia, exhausted lymphocytes, and pro-inflammatory cytokine production. Immunology is part of the process of clinical evolution, but there are some questions around immunity-based protection: (1) why some infected people have only mild symptoms of the disease or are asymptomatic; (2) why delayed and weak antibody responses are associated with severe outcomes; and (3) why positivity in molecular tests does not represent protective antibody IgG. Perhaps T cell responses may be the key to solving those questions. SARS-CoV-2-specific memory T cells persist in peripheral blood and may be capable of providing effective information about protective immunity. The T cells studies can be helpful in elucidating the pathways for development of vaccines, therapies, and diagnostics for COVID-19 and for filling these immunology knowledge gaps.","Cell Immunol","Melgaco, Juliana Gil","Azamor, Tamiris","Ano Bom, Ana Paula Dinis","32361409"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a severe acute respiratory syndrome that is called COVID-19. Clinical manifestations of COVID-19 include diarrhea, pneumonia, lymphopenia, exhausted lymphocytes, and pro-inflammatory cytokine production. Immunology is part of the process of clinical evolution, but there are some questions around immunity-based protection: (1) why some infected people have only mild symptoms of the disease or are asymptomatic; (2) why delayed and weak antibody responses are associated with severe outcomes; and (3) why positivity in molecular tests does not represent protective antibody IgG. Perhaps T cell responses may be the key to solving those questions. SARS-CoV-2-specific memory T cells persist in peripheral blood and may be capable of providing effective information about protective immunity. The T cells studies can be helpful in elucidating the pathways for development of vaccines, therapies, and diagnostics for COVID-19 and for filling these immunology knowledge gaps."],"journal":"Cell Immunol","authors":["Melgaco, Juliana Gil","Azamor, Tamiris","Ano Bom, Ana Paula Dinis"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361409","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cellimm.2020.104114","locations":["diarrhea","pneumonia","lymphopenia"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495497797632,"score":9.490897,"similar":[{"pmid":32396996,"title":"Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.","text":["Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.","As a zoonotic disease that has already spread globally to several million human beings and possibly to domestic and wild animals, eradication of coronavirus disease 2019 (COVID-19) appears practically impossible. There is a pressing need to improve our understanding of the immunology of this disease to contain the pandemic by developing vaccines and medicines for the prevention and treatment of patients. In this review, we aim to improve our understanding on the immune response and immunopathological changes in patients linked to detoriating clinical conditions such as, cytokine storm, acute respiratory distress syndrome, autopsy findings and changes in acute phase reactants and serum biochemistry in COVID-19. Similar to many other viral infections, asymptomatic disease is present in a significant but currently unknown fraction of the affected individuals.In the majority of the patients, a one-week, self-limiting viral respiratory disease typically occurs, which ends with the development of neutralizing anti-viral T cell and antibody immunity. The IgM, IgA and IgG type virus-specific antibodies levels are important measurements to predict population immunity against this disease and whether cross-reactivity with other coronaviruses is taking place.High viral-load during the first infection and repeated exposure to virus especially in healthcare workers can be an important factor for severity of disease. It should be noted that many aspects of severe patients are unique to COVID-19 and are rarely observed in other respiratory viral infections, such as severe lymphopenia and eosinopenia, extensive pneumonia and lung tissue damage, a cytokine storm leading to acute respiratory distress syndrome and multiorgan failure. Lymphopenia causes a defect in antiviral and immune regulatory immunity. At the same time, a cytokine storm starts with extensive activation of cytokine-secreting cells with innate and adaptive immune mechanisms both of with contribute to a poor prognosis. Elevated levels of acute phase reactants and lymphopenia are early predictors of high disease severity. Prevention of development to severe disease, cytokine storm, acute respiratory distress syndrome and novel approachs to prevent their development will be main routes for future research areas. As we learn to live amidst the virus, understanding the immunology of the disease can assist in containing the pandemic and in developing vaccines and medicines to prevent and treat individual patients.","Allergy","Azkur, Ahmet Kursat","Akdis, Mubeccel","Azkur, Dilek","Sokolowska, Milena","van de Veen, Willem","Bruggen, Marie-Charlotte","O'Mahony, Liam","Gao, Yadong","Nadeau, Kari","Akdis, Cezmi A","32396996"],"abstract":["As a zoonotic disease that has already spread globally to several million human beings and possibly to domestic and wild animals, eradication of coronavirus disease 2019 (COVID-19) appears practically impossible. There is a pressing need to improve our understanding of the immunology of this disease to contain the pandemic by developing vaccines and medicines for the prevention and treatment of patients. In this review, we aim to improve our understanding on the immune response and immunopathological changes in patients linked to detoriating clinical conditions such as, cytokine storm, acute respiratory distress syndrome, autopsy findings and changes in acute phase reactants and serum biochemistry in COVID-19. Similar to many other viral infections, asymptomatic disease is present in a significant but currently unknown fraction of the affected individuals.In the majority of the patients, a one-week, self-limiting viral respiratory disease typically occurs, which ends with the development of neutralizing anti-viral T cell and antibody immunity. The IgM, IgA and IgG type virus-specific antibodies levels are important measurements to predict population immunity against this disease and whether cross-reactivity with other coronaviruses is taking place.High viral-load during the first infection and repeated exposure to virus especially in healthcare workers can be an important factor for severity of disease. It should be noted that many aspects of severe patients are unique to COVID-19 and are rarely observed in other respiratory viral infections, such as severe lymphopenia and eosinopenia, extensive pneumonia and lung tissue damage, a cytokine storm leading to acute respiratory distress syndrome and multiorgan failure. Lymphopenia causes a defect in antiviral and immune regulatory immunity. At the same time, a cytokine storm starts with extensive activation of cytokine-secreting cells with innate and adaptive immune mechanisms both of with contribute to a poor prognosis. Elevated levels of acute phase reactants and lymphopenia are early predictors of high disease severity. Prevention of development to severe disease, cytokine storm, acute respiratory distress syndrome and novel approachs to prevent their development will be main routes for future research areas. As we learn to live amidst the virus, understanding the immunology of the disease can assist in containing the pandemic and in developing vaccines and medicines to prevent and treat individual patients."],"journal":"Allergy","authors":["Azkur, Ahmet Kursat","Akdis, Mubeccel","Azkur, Dilek","Sokolowska, Milena","van de Veen, Willem","Bruggen, Marie-Charlotte","O'Mahony, Liam","Gao, Yadong","Nadeau, Kari","Akdis, Cezmi A"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396996","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/all.14364","locations":["multiorgan"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666627827947012096,"score":192.26675},{"pmid":32413330,"pmcid":"PMC7196424","title":"Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.","text":["Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.","The World Health Organization has declared SARS-CoV-2 virus outbreak a worldwide pandemic. However, there is very limited understanding on the immune responses, especially adaptive immune responses to SARS-CoV-2 infection. Here, we collected blood from COVID-19 patients who have recently become virus-free, and therefore were discharged, and detected SARS-CoV-2-specific humoral and cellular immunity in eight newly discharged patients. Follow-up analysis on another cohort of six patients 2 weeks post discharge also revealed high titers of immunoglobulin G (IgG) antibodies. In all 14 patients tested, 13 displayed serum-neutralizing activities in a pseudotype entry assay. Notably, there was a strong correlation between neutralization antibody titers and the numbers of virus-specific T cells. Our work provides a basis for further analysis of protective immunity to SARS-CoV-2, and understanding the pathogenesis of COVID-19, especially in the severe cases. It also has implications in developing an effective vaccine to SARS-CoV-2 infection.","Immunity","Ni, Ling","Ye, Fang","Cheng, Meng-Li","Feng, Yu","Deng, Yong-Qiang","Zhao, Hui","Wei, Peng","Ge, Jiwan","Gou, Mengting","Li, Xiaoli","Sun, Lin","Cao, Tianshu","Wang, Pengzhi","Zhou, Chao","Zhang, Rongrong","Liang, Peng","Guo, Han","Wang, Xinquan","Qin, Cheng-Feng","Chen, Fang","Dong, Chen","32413330"],"abstract":["The World Health Organization has declared SARS-CoV-2 virus outbreak a worldwide pandemic. However, there is very limited understanding on the immune responses, especially adaptive immune responses to SARS-CoV-2 infection. Here, we collected blood from COVID-19 patients who have recently become virus-free, and therefore were discharged, and detected SARS-CoV-2-specific humoral and cellular immunity in eight newly discharged patients. Follow-up analysis on another cohort of six patients 2 weeks post discharge also revealed high titers of immunoglobulin G (IgG) antibodies. In all 14 patients tested, 13 displayed serum-neutralizing activities in a pseudotype entry assay. Notably, there was a strong correlation between neutralization antibody titers and the numbers of virus-specific T cells. Our work provides a basis for further analysis of protective immunity to SARS-CoV-2, and understanding the pathogenesis of COVID-19, especially in the severe cases. It also has implications in developing an effective vaccine to SARS-CoV-2 infection."],"journal":"Immunity","authors":["Ni, Ling","Ye, Fang","Cheng, Meng-Li","Feng, Yu","Deng, Yong-Qiang","Zhao, Hui","Wei, Peng","Ge, Jiwan","Gou, Mengting","Li, Xiaoli","Sun, Lin","Cao, Tianshu","Wang, Pengzhi","Zhou, Chao","Zhang, Rongrong","Liang, Peng","Guo, Han","Wang, Xinquan","Qin, Cheng-Feng","Chen, Fang","Dong, Chen"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413330","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.immuni.2020.04.023","keywords":["covid-19 patients","sars-cov-2","sars-cov-2-specific t cells","sars-cov-2-specific antibody","adaptive immunity"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666989866125099008,"score":175.49251},{"pmid":32469225,"title":"COVID-19 and the immune system.","text":["COVID-19 and the immune system.","A close interaction between the virus SARS-CoV-2 and the immune system of an individual results in a diverse clinical manifestation of the COVID-19 disease. While adaptive immune responses are essential for SARS-CoV-2 virus clearance, the innate immune cells, such as macrophages, may contribute, in some cases, to the disease progression. Macrophages have shown a significant production of IL-6 suggesting they may contribute to the excessive inflammation in COVID-19 disease. Macrophage Activation Syndrome may further explain the high serum levels of CRP, which are normally lacking in viral infections. In adaptive immune responses, it has been revealed that cytotoxic CD8+ T cells exhibit functional exhaustion patterns, such as the expression of NKG2A, PD-1, and TIM-3. Since SARS-CoV-2 restrains antigen presentation by downregulating MHC class I and II molecules and, therefore, inhibits the T cell-mediated immune responses, humoral immune responses also play a substantial role. Specific IgA response appears to be stronger and more persistent than IgM response. Moreover, IgM and IgG antibodies show similar dynamics in COVID-19 disease.","Physiol Res","Paces, J","Strizova, Z","Smrz, D","Cerny, J","32469225"],"abstract":["A close interaction between the virus SARS-CoV-2 and the immune system of an individual results in a diverse clinical manifestation of the COVID-19 disease. While adaptive immune responses are essential for SARS-CoV-2 virus clearance, the innate immune cells, such as macrophages, may contribute, in some cases, to the disease progression. Macrophages have shown a significant production of IL-6 suggesting they may contribute to the excessive inflammation in COVID-19 disease. Macrophage Activation Syndrome may further explain the high serum levels of CRP, which are normally lacking in viral infections. In adaptive immune responses, it has been revealed that cytotoxic CD8+ T cells exhibit functional exhaustion patterns, such as the expression of NKG2A, PD-1, and TIM-3. Since SARS-CoV-2 restrains antigen presentation by downregulating MHC class I and II molecules and, therefore, inhibits the T cell-mediated immune responses, humoral immune responses also play a substantial role. Specific IgA response appears to be stronger and more persistent than IgM response. Moreover, IgM and IgG antibodies show similar dynamics in COVID-19 disease."],"journal":"Physiol Res","authors":["Paces, J","Strizova, Z","Smrz, D","Cerny, J"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469225","source":"PubMed","week":"202022|May 25 - May 31","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887179689984,"score":173.73618},{"pmid":32458561,"title":"Lymphopenia in COVID-19: Therapeutic Opportunities.","text":["Lymphopenia in COVID-19: Therapeutic Opportunities.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncontrollably spread all over the world. The host immune responses strongly try to confront it with all the potential cells and cytokines. With chronically condition of SARS-CoV-2, NK cells and T cells become exhausted and decreasing their count leads to lymphopenia. Inability to eradicate the infected organ makes hyper-initiation of the immune system, which releases the excessive inflammatory cytokines to compensate the exhausted one as well as the low lymphocytes counts; it consequently lead to the cytokine storm syndrome. These mechanisms and the potential therapeutic targeting are discussed in this paper. This article is protected by copyright. All rights reserved.","Cell Biol Int","Fathi, Nazanin","Rezaei, Nima","32458561"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncontrollably spread all over the world. The host immune responses strongly try to confront it with all the potential cells and cytokines. With chronically condition of SARS-CoV-2, NK cells and T cells become exhausted and decreasing their count leads to lymphopenia. Inability to eradicate the infected organ makes hyper-initiation of the immune system, which releases the excessive inflammatory cytokines to compensate the exhausted one as well as the low lymphocytes counts; it consequently lead to the cytokine storm syndrome. These mechanisms and the potential therapeutic targeting are discussed in this paper. This article is protected by copyright. All rights reserved."],"journal":"Cell Biol Int","authors":["Fathi, Nazanin","Rezaei, Nima"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458561","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/cbin.11403","keywords":["apoptosis","covid-19","coronavirus","cytokine storm syndrome","hypercytokinemia","inflammation","lymphopenia","therapeutic"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967698924994560,"score":172.33711},{"pmid":32464584,"title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.","text":["The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.","BACKGROUND: SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute respiratory distress syndrome (ARDS), which can cause significant mortality, leading to concern that immunosuppressive treatments for multiple sclerosis and other disorders have significant risks for both infection and ARDS. OBJECTIVE: To examine the biology that potentially underpins immunity to the SARS-Cov-2 virus and the immunity-induced pathology related to COVID-19 and determine how this impinges on the use of current disease modifying treatments in multiple sclerosis. OBSERVATIONS: Although information about the mechanisms of immunity are scant, it appears that monocyte/macrophages and then CD8 T cells are important in eliminating the SARS-CoV-2 virus. This may be facilitated via anti-viral antibody responses that may prevent re-infection. However, viral escape and infection of leucocytes to promote lymphopenia, apparent CD8 T cell exhaustion coupled with a cytokine storm and vascular pathology appears to contribute to the damage in ARDS. IMPLICATIONS: In contrast to ablative haematopoietic stem cell therapy, most multiple-sclerosis-related disease modifying therapies do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19. In addition, few block the formation of immature B cells within lymphoid tissue that will provide antibody-mediated protection from (re)infection. However, adjustments to dosing schedules may help de-risk the chance of infection further and reduce the concerns of people with MS being treated during the COVID-19 pandemic.","Mult Scler Relat Disord","Baker, David","Amor, Sandra","Kang, Angray S","Schmierer, Klaus","Giovannoni, Gavin","32464584"],"abstract":["BACKGROUND: SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute respiratory distress syndrome (ARDS), which can cause significant mortality, leading to concern that immunosuppressive treatments for multiple sclerosis and other disorders have significant risks for both infection and ARDS. OBJECTIVE: To examine the biology that potentially underpins immunity to the SARS-Cov-2 virus and the immunity-induced pathology related to COVID-19 and determine how this impinges on the use of current disease modifying treatments in multiple sclerosis. OBSERVATIONS: Although information about the mechanisms of immunity are scant, it appears that monocyte/macrophages and then CD8 T cells are important in eliminating the SARS-CoV-2 virus. This may be facilitated via anti-viral antibody responses that may prevent re-infection. However, viral escape and infection of leucocytes to promote lymphopenia, apparent CD8 T cell exhaustion coupled with a cytokine storm and vascular pathology appears to contribute to the damage in ARDS. IMPLICATIONS: In contrast to ablative haematopoietic stem cell therapy, most multiple-sclerosis-related disease modifying therapies do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19. In addition, few block the formation of immature B cells within lymphoid tissue that will provide antibody-mediated protection from (re)infection. However, adjustments to dosing schedules may help de-risk the chance of infection further and reduce the concerns of people with MS being treated during the COVID-19 pandemic."],"journal":"Mult Scler Relat Disord","authors":["Baker, David","Amor, Sandra","Kang, Angray S","Schmierer, Klaus","Giovannoni, Gavin"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464584","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.msard.2020.102174","topics":["Prevention","Mechanism","Treatment"],"weight":1,"_version_":1668079521343995904,"score":168.52304}]}